Neurogene Inc. NGNE
$29.09
▲ +0.34% 24H
About
Neurogene Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases. Its primary purpose is to create purpose-built gene therapies using a biology-first approach, optimizing gene selection, construct design, expression control, and delivery to target neural sy…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees131
TickerNGNE
Statistics
Market Cap$454.3M
Revenue (TTM)$0
Net Income-$90.4M
Net Margin—
EPS$-4.24
P/E-6.84
P/S—
P/B1.89
EV/EBITDA-2.06
ROE-37.3%
Dividend Yield—
Price$29.09
Data: Twelve Data · Revenue = mcap / P/S